[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jade Biosciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100633381","phase-1-a-single-dose-phase-1-study-of-jade101-in-healthy-japanese-and-chinese-participants-100633381",false,"NCT07525947","A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants","A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.","Inclusion Criteria:\n\n1. Healthy male or female participants 18-55 years of age, inclusive\n2. First-generation Japanese or Chinese participants born in Japan\u002FChina\n3. A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg\u002Fm2 (all inclusive) at screening\n4. Willing and able to comply with the study site stay, scheduled visits, and study procedures\n5. Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study\n\nExclusion Criteria:\n\n1. Harmful alcohol use\n2. Smoking\u002Fvaping or heavy tobacco use within 2 years prior to screening\n3. Known history of abuse of illicit drugs\n4. Nursing, lactating or pregnant, or who have plans to become pregnant during the study\n5. Known history of clinically significant disease\n6. Known history of immunodeficiency disorder\n7. History of clinically significant allergic reactions or hypersensitivity",true,"ALL","18 Years","55 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.",[28],"Healthy Volunteers (HV)",[30],"JADE101","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2026-05-01",{"date":39,"type":22},"2027-05",{"name":41,"class":42},"Jade Biosciences, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100633997","phase-1-a-phase-1-study-of-jade201-in-participants-with-rheumatoid-arthritis-100633997","NCT07533955","A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis","A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE201 Administered Subcutaneously in Participants With Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Male and female participants 18-70 years of age, inclusive.\n2. A body weight between 50-100 kg and a body mass index (BMI) between 18-32 kg\u002Fm2 (all inclusive) at screening.\n3. Confirmed diagnosis of RA according to 2010 ACR\u002FEULAR criteria\n4. Willing and able to comply with the inpatient stay at the site, scheduled visits, treatment plans, laboratory tests, and other study procedures specified in the protocol.\n5. Willing and able to comply with contraceptive and lifestyle requirements specified in the protocol.\n\nExclusion Criteria:\n\n1. With the exception of RA, known history of clinically significant disease\n2. Diagnosis or symptoms suggestive of any systemic autoimmune or inflammatory condition other than RA\n3. positive serology for Hep A, Hep B, or Hep C virus\n4. Positive, indeterminate, or invalid test of TB\n5. Current tobacco users who smoke \\>5 cigarettes per day or equivalent\n6. Nursing, lactating or pregnant, or who have plans to become pregnant during the study\n7. Treatment with an investigational drug within 30 days or 5 half lives prior to study drug administration","70 Years",{"count":53,"type":22},36,[25],"This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis",[57],"Rhematoid Arthritis","2026-05-27",{"date":60,"type":35},"2026-06-01",{"date":62,"type":35},"2026-05-19",{"date":64,"type":22},"2028-10",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100634561","phase-2-a-study-of-jade101-in-participants-with-immunoglobulin-a-nephropathy-100634561","NCT07541287","A Study of JADE101 in Participants With Immunoglobulin A Nephropathy","A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)","Inclusion Criteria:\n\n1. Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent\n2. eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2\n3. Biopsy-confirmed primary IgAN\n4. Receiving stable and maximally tolerated doses of either ACEi or ARB as per standard of care (SoC) and applicable guidelines for at least 12 weeks prior to the initial screening visit, with no intention to alter the dose or discontinue treatment, unless medically necessary\n5. UPCR ≥ 0.75 g\u002Fg\n6. Willing to provide written informed consent\n7. Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, and other study procedures\n8. Willing and able to comply with contraceptive and lifestyle requirements\n\nExclusion Criteria:\n\n1. Secondary forms of IgAN\n2. Known or suspected coexisting Chronic Kidney Disease (CKD) other than IgAN\n3. Known or suspected rapidly progressive glomerulonephritis (RPGN)\n4. Evidence of pathological findings in the kidney biopsy in addition to IgAN (eg, minimal change disease, diabetic kidney disease, membranous nephropathy, focal segmental glomerulosclerosis, or lupus nephritis); hypertensive vascular changes are acceptable\n5. Known or suspected primary or secondary immunodeficiency disorder\n6. Evidence of tuberculosis infection at screening\n7. Any chronic infectious disease\n8. Any acute infectious disease at time of screening\n9. Received bone marrow, hematologic stem cell transplantation, or a solid organ transplant, including kidney\n10. Known or suspected alcohol or drug abuse\n11. Any clinically significant and\u002For unstable or uncontrolled medical condition as assessed by the investigator\n12. Malignancy within the past 5 years; nonmelanoma skin cancer and curatively treated cervical carcinoma in situ are allowed\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","60 Years",{"count":75,"type":22},30,[77],"PHASE2","This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.",[80],"IgA Nephropathy",[82,83,84,85,86,87,88,89,90,91],"Glomerulonephritis","Nephritis","Nephropathy","Kidney Diseases","Urologic Diseases","Urogenital Diseases","Autoimmune Diseases","Immune System Diseases","Proteinuria","Glomerulonephritis, IGA","2026-05-26",{"date":94,"type":35},"2026-05-29",{"date":62,"type":35},{"date":97,"type":22},"2029-04",{"name":41,"class":42},7,""]